Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998064 | 0.76 | ALDH1A1 (0.55) | TRPV1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL998142 | 0.75 | TRPV1 (0.78) | TRPV1CDK4CCND1 | |
| SCHEMBL999397 | 0.74 | TRPV1 (0.49) | OPRM1OGFRL1TRPV1KMT2AMEN1 | |
| SCHEMBL996814 | 0.73 | TRPV1 (0.69) | TRPV1ALDH1A1RAB9ACDK4CCND1 | |
| SCHEMBL1000695 | 0.73 | TRPV1 (0.61) | TRPV1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL998250 | 0.70 | MAPT (0.71) | TRPV1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL2141092 | 0.70 | OPRM1 (0.52) | OPRM1OGFRL1TRPV1KMT2ALMNA | |
| SCHEMBL2141401 | 0.69 | OPRM1 (0.62) | OPRM1OGFRL1LMNATP53CDK4 | |
| SCHEMBL9439636 | 0.69 | TRPV1 (0.59) | TRPV1ALDH1A1CDK4CCND1 | |
| SCHEMBL9439699 | 0.69 | TRPV1 (0.59) | TRPV1ALDH1A1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | OPRM1 1743/4885OGFRL1 2821/4885TRPV1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.